Successful fetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy--a case report

American Journal of Perinatology
H L ClaahsenV Mattijssen

Abstract

Chemotherapeutic agents administered to the mother during pregnancy may severely jeopardize the fetus. We describe a newborn girl who had been exposed to idarubicin and cytosine-arabinoside during the second and third trimesters of pregnancy due to treatment of newly diagnosed acute myeloid leukemia in the mother. The child had no structural congenital abnormalities. Adverse effects observed were prematurity, growth retardation, mildly disturbed transaminases and erythroblastosis, all of which were self-limiting with no permanent sequelae.

Citations

Oct 7, 2005·Pharmacotherapy·Dawn M NiedermeierPhilip D Hall
Aug 2, 2012·Birth Defects Research. Part A, Clinical and Molecular Teratology·Brady P SeligJohn J Mulvihill
May 26, 2004·Pediatric Clinics of North America·Enrique M OstreaMaria Asuncion Silvestre
Aug 15, 2000·American Journal of Obstetrics and Gynecology·C Achtari, P Hohlfeld
Nov 26, 2013·Blood·Dragana Milojkovic, Jane F Apperley
Nov 11, 2015·Best Practice & Research. Clinical Obstetrics & Gynaecology·Siew-Fei Ngu, Hextan Y S Ngan
Jan 18, 2007·Neurotoxicology·M De SantisA Caruso
Sep 11, 2009·Best Practice & Research. Clinical Obstetrics & Gynaecology·Frédéric AmantKristel Van Calsteren
Sep 27, 2014·The Annals of Pharmacotherapy·Abraham Chang, Samit Patel
Jul 17, 2004·Gynecologic and Obstetric Investigation·Koji MatsuoYuji Murata
Jul 30, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B L SiuA L Fenrich
May 11, 2018·Leukemia·Sabine KayserUwe Platzbecker
Oct 9, 2002·Clinical Obstetrics and Gynecology·Tanja Pejovic, Peter E Schwartz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology
A D Falconer, P Ferns
© 2022 Meta ULC. All rights reserved